JP Morgan Chase
HRTX icon

JP Morgan Chase’s Heron Therapeutics HRTX Stock Holding History

JP Morgan Chase’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$3K – 5595
2020
Q2 		$3K Buy
+200
New +$3.29K ﹤0.01% 5233
2018
Q3 		– Sell
-220,000
Closed -$8.55M – 5729
2018
Q2 		$8.55M Buy
+220,000
New +$7M ﹤0.01% 2265

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

JP Morgan Chase's HRTX Position: Q1 2026 in Review

JP Morgan Chase increased its Heron Therapeutics (HRTX) stake by 4.3% in Q1 2026, buying an estimated $3.14K and bringing the position to 65,106 shares worth $48.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6211.

JP Morgan Chase first reported a position in HRTX in Q4 2014 and has held it in 44 quarters since. The position peaked at $70M in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • JP Morgan Chase held 65,106 shares of Heron Therapeutics worth $48.6K as of Q1 2026.
  • JP Morgan Chase bought 2,710 Heron Therapeutics shares in Q1 2026, an estimated $3.14K.
  • Heron Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6211 holding.
  • JP Morgan Chase first reported a position in Heron Therapeutics in Q4 2014 and has held it in 44 quarters since.
  • JP Morgan Chase's Heron Therapeutics position peaked at $70M in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.